Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15893902 | 0.92 | SMN1; SMN2 (0.50) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL21795553 | 0.82 | CA12 (0.50) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL22093201 | 0.82 | CA12 (0.50) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL13100462 | 0.82 | — | — | |
| SCHEMBL25107208 | 0.81 | SMN1; SMN2 (0.44) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL21795443 | 0.79 | CA12 (0.46) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL18921916 | 0.78 | CA12 (0.34) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL12449171 | 0.77 | CA12 (0.50) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL5405216 | 0.77 | EPHX2 (0.44) | TSHRALDH1A1POLBEPHX2CYP2C9 | |
| SCHEMBL16022965 | 0.77 | EPHX2 (0.44) | SMN1; SMN2TSHRL3MBTL1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023235880-A1 | CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023212693-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230277505-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-09-07 | — | — | US | disclosed |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230241074-A1 | INHIBITORS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS | Atomwise Inc. | 2023-08-03 | — | — | US | disclosed |
| US-20230241074-A1 | INHIBITORS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS | Atomwise Inc. | 2023-08-03 | — | — | US | disclosed |
| US-20230146507-A1 | N-PHENYL-3-MERCAPTOPROPANAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2023-05-11 | — | — | US | disclosed |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20090030015-A1 | NOVEL MULTI-CYCLIC COMPOUNDS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2009-01-29 | — | — | US | disclosed |
| US-7470699-B2 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7419978-B2 | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080207639-A1 | Novel Aromatic Compounds and Their Use in Medical Applications | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2008-08-28 | — | — | US | disclosed |
| US-7358250-B2 | Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity | AMGEN INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7309716-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-18 | — | — | US | disclosed |
| US-7309716-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-18 | — | — | US | disclosed |
| US-7250444-B2 | Pyrrole-based HMG-CoA reductase inhibitors | PFIZER INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | CA12 4588/4885CA7 3193/4885CA14 4612/4885 |
| US-20230241074-A1 | INHIBITORS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS | MAVS, PIGS, SARS1 | CA12 3932/4885CA7 3496/4885CA14 2974/4885 |
| US-20080207639-A1 | Novel Aromatic Compounds and Their Use in Medical Applications | SELP, SELL, SELE | CA12 4269/4885CA7 4614/4885CA14 4407/4885 |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | KIF18A, KIF18B, KIF2C | CA12 4214/4885CA7 4209/4885CA14 4172/4885 |
| US-20230146507-A1 | N-PHENYL-3-MERCAPTOPROPANAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, PREP, MME | CA12 3394/4885CA7 2929/4885CA14 3270/4885 |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | JAK1, JAK3, MAP3K4 | CA12 4874/4885CA7 4518/4885CA14 4706/4885 |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | CA12 4862/4885CA7 4758/4885CA14 4877/4885 |
| US-20090030015-A1 | NOVEL MULTI-CYCLIC COMPOUNDS | SELP, SELE, SELL | CA12 2349/4885CA7 4380/4885CA14 3208/4885 |
| US-20230277505-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR2C | CA12 4849/4885CA7 4865/4885CA14 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.